## Molecular Therapy Methods & Clinical Development

Correction



## AAV vector production: Troublesome host innate responses in another setting

J. Fraser Wright

**Correspondence:** fraser.wright@stanford.edu https://doi.org/10.1016/j.omtm.2023.08.001

(Molecular Therapy: Methods & Clinical Development 28, 412-413; March 2023)

In the originally published version of this article, Table 1 contained two incorrect monoclonal antibody volumetric productivity ranges. The molecules/L value should be 1.6– $4.0 \times 10^{19}$  instead of 400– $3,200 \times 10^{15}$ , and the g/L value should be 4–10 instead of 0.1–0.8. The revised numbers do not change the message conveyed; rather, they even more strongly emphasize the gap in productivity between rAAV and monoclonal antibodies in cell culture.

These changes have been made online, and the author apologizes for any inconvenience this may have caused.

